Alpha-enolase plasminogen receptor in myogenesis.
Plasmin is a potent extracellular protease specialized in the degradation of fibrin (fibrinolysis). Active plasmin is generated by proteolytic activation of the zymogen plasminogen (Plg) by urokinase-type plasminogen activator (uPA) and tissue-type plasminogen activator (tPA). Alpha-enolase, although traditionally considered a glycolytic enzyme, constitutes a receptor for plasminogen on several cell types, serving to localize and promote plasminogen activation pericellularly. Localization of plasmin activity on the cell surface plays a critical role in fibrinolysis and in physiopathological processes involving extracellular matrix remodelling. Previous studies have unambiguously demonstrated that uPA-dependent plasmin generation is necessary for myogenesis in vitro and for muscle regeneration in vivo. However, the implication of alpha-enolase plasminogen receptor in myogenesis had never been investigated. This review focuses on the recently reported expression and function of alpha-enolase plasminogen receptor during myogenesis. Skeletal myoblasts express alpha-enolase plasminogen receptor, being its expression greatly induced during the differentiation process in vitro. MAb 11G1, a monoclonal antibody against anti-alpha-enolase plasminogen receptor, that inhibits plasmin generation, was able to fully abrogate myoblast fusion and differentiation. Moreover, both plasmin activity and alpha-enolase plasminogen receptor expression were significantly augmented in injury-induced regenerating muscle of wild type mice and in the dystrophic muscle of mdx mice, an animal model of Duchenne muscular dystrophy (DMD). Altogether, these results indicate that the plasminogen activation (PA) system is an important component of skeletal myogenesis in vitro and in vivo. In particular, the expression of alpha-enolase plasminogen receptor may serve to concentrate and enhance plasmin generation on the cell surface of migratory myoblasts contributing to efficient muscle repair.
Lopez-Alemany
Roser
R
Institut de Recerca Oncologica, Centre d'Oncologia Molecular, L'Hospitalet de Llobregat, Barcelona, Spain. rlopez@iro.es <rlopez@iro.es>
Suelves
Monica
M
Diaz-Ramos
Angels
A
Vidal
Berta
B
Munoz-Canoves
Pura
P
D000818:Animals; D000911:Antibodies, Monoclonal / Q000737:chemistry; D014408:Biomarkers, Tumor / Q000502:physiology*; D004268:DNA-Binding Proteins / Q000502:physiology*; D004195:Disease Models, Animal; D005109:Extracellular Matrix; D006019:Glycolysis; D006801:Humans; D051379:Mice; D018101:Mice, Inbred mdx; D024510:Muscle Development; D018482:Muscle, Skeletal / Q000378:metabolism; D020388:Muscular Dystrophy, Duchenne / Q000378:metabolism; D010751:Phosphopyruvate Hydratase / Q000502:physiology*; D010959:Tissue Plasminogen Activator / Q000378:metabolism*; D025521:Tumor Suppressor Proteins / Q000502:physiology*; D014568:Urokinase-Type Plasminogen Activator / Q000378:metabolism*
D000911:Antibodies, Monoclonal; D014408:Biomarkers, Tumor; D004268:DNA-Binding Proteins; D025521:Tumor Suppressor Proteins; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator; C095157:ENO1 protein, human; D010751:Phosphopyruvate Hydratase